Long-term dupilumab therapy reduces concomitant medication use in patients with CRSwNP.

Key Points

• The aim is to evaluate the impact of dupilumab therapy on medication use and disease control in chronic rhinosinusitis with nasal polyps (CRSwNP).
• Real-world cohort design
• Assessment of medication use pre and post-dupilumab therapy
• Evaluation of overall disease control
• Dupilumab treatment significantly reduced concomitant medication usage
• Improvement in overall disease control reported
• Lowered pharmacological burden observed in patients